“…PDE5 inhibitors restore nitric oxide (Kalsi et al, 2005;Lee et al, 2022) and are selective vasodilators of the NO-cGMP signaling pathway (Aversa et al, 2019;Ahmed et al, 2021). PDE5 inhibitors have been shown to benefit vasculature oxygenation (Morelli et al, 2011;Michel et al, 2015), prevent ischemia-hypoxia (Saito et al, 2014;Zarifpour et al, 2015;Fujii et al, 2019), and reduce microvascular/endothelial dysfunction (Cellek et al, 2014;Ölmestig et al, 2020;Statsenko and Urologiia, 2021); they also reduce oxidative stress (Matsuo et al, 2020), inflammation (Vignozzi et al, 2013;Peixoto and Gomes, 2015), amyloids (Kang et al, 2022), and prostate weight (Kobayashi et al, 2022).…”